Prototype Ferrari LaFerrari Mule Heads to Auction at Monterey Car Week
RM Sotheby'sis offering a rare piece ofFerraridevelopment history duringMonterey Car Week: the 2011Ferrari LaFerrariPrototype M4, expected to fetch between $900,000 and $1,200,000 USD. Internally referred to as 'F150 Muletto M4,' this early test mule was part of the first phase of real-world development for the hybrid LaFerrari and features a hybrid V-12 powertrain mounted on a heavily modified458 Italiachassis.
While the interior still resembles a 458, with black leather seats, tan carpets and a 9,000-rpm white tachometer, the car's dashboard toggle switch and high-voltage warning label hint at its experimental purpose. On the outside, aggressive design cues like exposed rivets, large front air intakes, mismatched brakes, side-mounted powertrain access hatches and high-rise air intakes make it unmistakably a prototype. Though not homologated for road or track use, this development mule represents a critical step in Ferrari's transition to hybrid hypercars and stands as a captivating collector's item for Ferrari enthusiasts. Bidding is set to open on August 15 as part of RM Sotheby'sMonterey sale.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Zydus Lifesciences gets USFDA final approval for Diltiazem Hydrochloride tablets
By Aman Shukla Published on August 11, 2025, 10:10 IST Zydus Lifesciences Limited, along with its subsidiaries and affiliates (collectively referred to as 'Zydus'), has secured final approval from the United States Food and Drug Administration (USFDA) for its Diltiazem Hydrochloride Tablets USP in multiple strengths: 30 mg, 60 mg, 90 mg, and 120 mg. These tablets will be marketed under the brand name Cardizem® Tablets in the US. Diltiazem Hydrochloride Tablets are widely prescribed for managing chronic stable angina and angina caused by coronary artery spasms. Classified as calcium-channel blockers, these tablets work by relaxing blood vessels, thereby reducing the heart's workload and improving blood and oxygen flow to the heart muscle. This approval allows Zydus to manufacture the drug at its state-of-the-art facility in Baddi, Himachal Pradesh. According to IQVIA MAT data from June 2025, Diltiazem Hydrochloride Tablets generated annual sales of USD 13.9 million in the United States, highlighting the product's strong market demand. With this recent approval, Zydus has achieved a total of 423 USFDA approvals and has filed 483 ANDAs (Abbreviated New Drug Applications) since it began filing in the fiscal year 2003-04. This milestone underscores Zydus' commitment to expanding its footprint in the competitive US pharmaceutical market. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
4 hours ago
- Business Upturn
Mini Diamonds shares jump on securing Rs 18.29 crore export order from Hong Kong client
By Aditya Bhagchandani Published on August 11, 2025, 09:49 IST Shares of Mini Diamonds (India) Ltd rose on Monday after the company announced securing an export order worth USD 21,50,000 (approximately Rs 18.29 crore) for lab-grown cut and polished diamonds from a prominent Hong Kong–based client. The order, placed on August 11, 2025, will be executed within three months, with payment scheduled within 150 days. The company said this marks its entry into the Hong Kong market, a global hub for diamond trading, strengthening its presence in the Far East. Mini Diamonds' Chairman and Managing Director, Upendra N. Shah, said the order highlights growing international confidence in the company's quality and aligns with its long-term strategy to expand exports and diversify its customer base. Mini Diamonds manufactures diamonds and jewellery at its Mumbai facility, equipped with advanced technology such as Sarin machines, auto bruiting systems, and semi-automatic polishing mills. The deal was awarded by Jewellery Trendz Ltd, with delivery expected within the stipulated three-month period. The company expects the order to boost export revenues and open new opportunities in the Far East jewellery market. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
5 hours ago
- Yahoo
Rupee to rise at open on NDF lift; U.S. tariffs, inflation on radar
By Nimesh Vora MUMBAI (Reuters) -The rupee is set to open higher on Monday, supported by its recovery in the non-deliverable forward market, while traders remain focused on potential fallout from U.S. tariffs and the upcoming U.S. inflation data. The 1-month non-deliverable forward indicated the rupee will open in the 87.52-87.56 range versus the U.S. dollar, compared with 87.66 on Friday. The NDF move feels "purely positional" and there was no real shift in underlying sentiment, a currency trader at a Mumbai-based bank said, with the structural bias on USD/INR remaining higher till the tariff overhang is in play. The tactical adjustment in NDF likely reflects some trimming of heavy-dollar positions, with the Reserve Bank of India's intervention likely prompting speculators who were betting on a quick leg higher in USD/INR to think twice, the trader said. Over the last two weeks, the RBI has intervened in the non-deliverable forward and onshore spot markets to cushion the rupee against tariff pressures stemming from U.S. President Donald Trump's actions. SOFT US DOLLAR A broadly softer dollar, on growing bets of a Federal Reserve rate cut next month, is expected to aid the rupee amid the tariff noise. The dollar index fell on Monday, extending losses from last week, while most Asian currencies advanced. July U.S. inflation data, due on Tuesday, will be key to gauging Fed rate-cut expectations and the dollar's direction. While the full impact of the latest tariffs may take time to filter into the inflation numbers, the July print will still be heavily scrutinised, MUFG Bank said in a note, adding that June data already showed signs that tariff rates are starting to have a bigger impact. Traders currently see a 90% chance of a September Fed rate cut and are pricing in just over two cuts for the year. KEY INDICATORS: ** One-month non-deliverable rupee forward at 87.66; onshore one-month forward premium at 12 paise ** Dollar index down at 98.08 ** Brent crude futures down 0.5% at $66.3 per barrel ** Ten-year U.S. note yield at 4.28% ** As per NSDL data, foreign investors sold a net $629.4 million worth of Indian shares on Aug 7 ** NSDL data shows foreign investors bought a net $69.1 million worth of Indian bonds on Aug 7 Sign in to access your portfolio
